Finally, pterostilbene dietary supplementation provided to a prostate-specific MTA1-overexpressing transgenic mouse model mimicking high-risk premalignant prostate cancer (R26MTA1, Pten+/f; Cre+) resulted in an MTA1-mediated (Cyclin D1, Notch2, IL-6, IL-1β, miR-22, miR-34a) reduction in tumor growth and progression, favorable histopathology and reduced angiogenesis, highlighting the potential for oral pterostilbene in prostate cancer [50]. This evidence concerns the gene MTA1 and prostate cancer.